NAS8
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
02/24/2026
Back to search
Official data from USPTO
CRISPR THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
50
Latest update
02/25/2026
Trademark type
Combined
Nice classes
41, 42
Filing date
04/11/2018
Registration date
11/19/2019
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/24/2026
Last transaction
02/25/2026
Responsible office
United States Patent and Trademark Office
Status code
701
Official register
Supplemental Register
First use anywhere
2013-11-00
First use in commerce
2013-11-00
Drawing code
3
Owner type
99
Owner location
ZUG V8, CH
Examiner
SCHIMPF, TIMOTHY O
Current location
Historical data usage
Mark description
The mark consists of an incomplete square with a break in the lower right of the square. At the bottom of the square below the break appears a shaded rectangle. In the lower middle of the square appears the stylized word "CRISPR", with the second "R" connected to the square. In the shaded rectangle appears the stylized word "THERAPEUTICS".
Holders and representatives
Holders
CRISPR Therapeutics AG
CRISPR Therapeutics AG
Representatives
Tiffany D. Gehrke Marshall Gerstein & Borun LLP
Technical classification
Nice Classes
Class 41Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 41
Education servicesproviding online non-downloadable articles and newsletters in the fields of pharmaceuticalsgeneticsgenome editinggene editinggenome engineeringgene modulationtranscriptional regulationtranscriptional modulationgenetic diseasesgene therapy and cell therapy
Class 42
Scientific research and developmentgene editing for researching and developing human cells and pharmaceuticals; research and development of therapeutics pharmaceuticals using gene editing; pharmaceuticalmedicalscientificbiopharmaceutical research and development; medical laboratory services; scientific laboratory services; custom cell-line engineering services; medical and scientific research in the fields of pharmaceuticalsgeneticsgenome editinggene editinggenome engineeringgene modulationtranscriptional regulationtranscriptional modulationgenetic diseasesgene therapy and cell therapy; providing medical research and scientific research information in the fields of pharmaceuticalsgeneticsgenome editinggene editinggenome engineeringgene modulationtranscriptional regulationtranscriptional modulationgenetic diseasesgene therapy and cell therapy; scientific research and development services relating to targeting genetic therapies to individuals
Publications
History of USPTO decisions and trademark events.
50 publications found
8.OK
REGISTERED - SEC. 8 (6-YR) ACCEPTED
02/24/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
02/23/2026
ES8R
TEAS SECTION 8 RECEIVED
10/03/2025
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
11/19/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
04/28/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/28/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/28/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/28/2021
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
04/28/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
08/07/2020
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
08/07/2020
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
08/07/2020
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
08/07/2020
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
08/05/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
08/05/2020
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
08/05/2020
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
08/05/2020
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
08/05/2020
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
08/05/2020
R.SR
REGISTERED-SUPPLEMENTAL REGISTER
11/19/2019
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
10/11/2019
CNTA
APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER
10/01/2019
XAEC
EXAMINER'S AMENDMENT ENTERED
09/25/2019
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
09/25/2019
GNEA
EXAMINERS AMENDMENT E-MAILED
09/25/2019
CNEA
EXAMINERS AMENDMENT -WRITTEN
09/25/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/13/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/13/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/10/2019
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/26/2019
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/26/2019
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
03/21/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
03/13/2019
GNRT
NON-FINAL ACTION E-MAILED
03/13/2019
CNRT
NON-FINAL ACTION WRITTEN
03/13/2019
DPCC
DIVISIONAL PROCESSING COMPLETE
02/21/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/21/2019
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
02/13/2019
ALIE
ASSIGNED TO LIE
02/12/2019
DRRR
DIVISIONAL REQUEST RECEIVED
02/07/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/07/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/07/2019
ERTD
TEAS REQUEST TO DIVIDE RECEIVED
02/07/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
08/07/2018
GNRT
NON-FINAL ACTION E-MAILED
08/07/2018
CNRT
NON-FINAL ACTION WRITTEN
08/07/2018
DOCK
ASSIGNED TO EXAMINER
07/31/2018
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
04/20/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/19/2018
Continuous trademark protection
Get notified about every new filing that threatens CRISPR THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.